Literature DB >> 12918103

Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma.

Wei-Jian Guo1, Er-Xin Yu, Lu-Ming Liu, Jie Li, Zhen Chen, Jun-Hua Lin, Zhi-Qiang Meng, Yi Feng.   

Abstract

AIM: To investigate the efficacy of transcatheter arterial chemoembolization (TACE) combined with radiotherapy for unresectable large hepatocellular carcinoma (HCC).
METHODS: From June 1994 to June 1999, a total of 76 patients with large unresectable HCC were treated with TACE followed by external-beam irradiation. 89 patients with large HCC, who underwent TACE alone during the same period, served as the control group. Clinical features, therapeutic modalities, acute effects and survival rates were analyzed and compared between TACE plus irradiation group and TACE alone group. A multivariate analysis of nine clinical variables and one treatment variable (irradiation) was performed by the Cox proportional hazards model.
RESULTS: The clinical features and therapeutic modalities except irradiation between the two groups were comparable (P>0.05). The objective response rate (RR) in TACE plus irradiation group was higher than that in TACE alone group (47.4 % vs 28.1 %, P<0.05). The overall survival rates in TACE plus irradiation group (64.0 %, 28.6 %, and 19.3 % at 1, 3, 5 years, respectively) were significantly higher than those in TACE alone group (39.9 %, 9.5 %, and 7.2 %, respectively, P=0.0001). Cox proportional hazards model analysis showed that tumor extension and Child grade were significant and were independent negative predictors of survival, while irradiation was an independent positive predictor of survival.
CONCLUSION: TACE combined with radiotherapy is more effective than TACE alone, and is a promising treatment for unresectable large HCC.

Entities:  

Mesh:

Year:  2003        PMID: 12918103      PMCID: PMC4611526          DOI: 10.3748/wjg.v9.i8.1697

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

1.  [Prognostic factors influencing survival in patients with large hepatocellular carcinoma receiving combined transcatheter arterial chemoembolization and radiotherapy].

Authors:  Weijian Guo; Erxin Yu; Chen Yi; Wanyin Wu; Junhua Lin
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2002-06

2.  Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization.

Authors:  J Chia-Hsien Cheng; V P Chuang; S H Cheng; Y M Lin; T I Cheng; P S Yang; J J Jian; D L You; C F Horng; A T Huang
Journal:  Int J Cancer       Date:  2001-08-20       Impact factor: 7.396

3.  Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors.

Authors:  K Ueno; N Miyazono; H Inoue; H Nishida; I Kanetsuki; M Nakajo
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

4.  Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma.

Authors:  J Seong; S H Kim; C O Suh
Journal:  J Gastroenterol Hepatol       Date:  2001-08       Impact factor: 4.029

5.  Radiotherapy for hepatocellular carcinoma.

Authors:  K Tokuuye; M Sumi; Y Kagami; S Murayama; M Kawashima; H Ikeda; H Ueno; T Okusaka; S Okada
Journal:  Strahlenther Onkol       Date:  2000-09       Impact factor: 3.621

6.  Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study.

Authors:  Hyo-Suk Lee; Kang Mo Kim; Jung-Hwan Yoon; Tae-Rim Lee; Kyung Suk Suh; Kuhn Uk Lee; Jin Wook Chung; Jae Hyung Park; Chung Yong Kim
Journal:  J Clin Oncol       Date:  2002-11-15       Impact factor: 44.544

7.  Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.

Authors:  H B El-Serag; A C Mason; C Key
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

8.  A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases.

Authors:  J M Robertson; C J McGinn; S Walker; M V Marx; M L Kessler; W D Ensminger; T S Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-12-01       Impact factor: 7.038

9.  Phase I clinical trial of oral furtulon and combined hepatic arterial chemoembolization and radiotherapy in unresectable primary liver cancers, including clinicopathologic study.

Authors:  Z C Zeng; Z Y Tang; Z Q Wu; Z C Ma; J Fan; L X Qin; J Zhou; J H Wang; B L Wang; C S Zhong
Journal:  Am J Clin Oncol       Date:  2000-10       Impact factor: 2.339

10.  Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.

Authors:  G Pelletier; M Ducreux; F Gay; M Luboinski; H Hagège; T Dao; W Van Steenbergen; C Buffet; P Rougier; M Adler; J P Pignon; A Roche
Journal:  J Hepatol       Date:  1998-07       Impact factor: 25.083

View more
  24 in total

1.  Post-radiation survival time in hepatocellular carcinoma based on predictors for CT-determined, transarterial embolization and various other parameters.

Authors:  Ting-Kai Leung; Chi-Ming Lee; Li-Kuo Shen; Hsi-Chi Chen; Yu-Cheng Kuo; Jeng-Fong Chiou
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

Review 2.  Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review.

Authors:  Maria-Aggeliki Kalogeridi; Anna Zygogianni; George Kyrgias; John Kouvaris; Sofia Chatziioannou; Nikolaos Kelekis; Vassilis Kouloulias
Journal:  World J Hepatol       Date:  2015-01-27

3.  Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma.

Authors:  Do Seon Song; Soon Woo Nam; Si Hyun Bae; Jin Dong Kim; Jeong Won Jang; Myeong Jun Song; Sung Won Lee; Hee Yeon Kim; Young Joon Lee; Ho Jong Chun; Young Kyoung You; Jong Young Choi; Seung Kew Yoon
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

Review 4.  Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

5.  p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up.

Authors:  Yong-Song Guan; Yuan Liu; Qing He; Xiao Li; Lin Yang; Ying Hu; Zi La
Journal:  World J Gastroenterol       Date:  2011-04-28       Impact factor: 5.742

6.  Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.

Authors:  De-Hua Wu; Li Liu; Long-Hua Chen
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

7.  Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma.

Authors:  Jeffrey M Vainshtein; Rafi Kabarriti; Keyur J Mehta; Jayanta Roy-Chowdhury; Chandan Guha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-15       Impact factor: 7.038

8.  Treatment of malignant biliary obstruction by combined percutaneous transhepatic biliary drainage with local tumor treatment.

Authors:  Xiao-Jun Qian; Ren-You Zhai; Ding-Ke Dai; Ping Yu; Li Gao
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

9.  Anti-tumor effect of pEgr-IFNgamma gene-radiotherapy in B16 melanoma-bearing mice.

Authors:  Cong-Mei Wu; Xiu-Yi Li; Tian-Hua Huang
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

10.  Assessment of hepatocellular carcinoma vascularity before and after transcatheter arterial chemoembolization by using first pass perfusion weighted MR imaging.

Authors:  Jun-Gong Zhao; Gan-Sheng Feng; Xiang-Quan Kong; Xin Li; Ming-Hua Li; Ying-Sheng Cheng
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.